Thomas H. Marsilje, Ph.D.
Affiliations: | 2000 | State University of New York, Buffalo, Buffalo, NY, United States |
Area:
Organic Chemistry, Pharmaceutical Chemistry, BiochemistryGoogle:
"Thomas Marsilje"Mean distance: (not calculated yet)
Parents
Sign in to add mentorDavid G. Hangauer | grad student | 2000 | SUNY Buffalo | |
(Design, synthesis and biological evaluation of peptidyl and non-peptidyl inhibitors of the pp60(c-src) protein tyrosine kinase which do not compete with ATP.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Jia Y, Yun CH, Park E, et al. (2016) Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 534: 129-32 |
Fairhurst RA, Marsilje TH, Stutz S, et al. (2016) Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors. Bioorganic & Medicinal Chemistry Letters |
Jia Y, Juarez J, Li J, et al. (2016) EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Research |
Michellys PY, Chen B, Jiang T, et al. (2015) Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors. Bioorganic & Medicinal Chemistry Letters |
Marsilje TH, Pei W, Chen B, et al. (2013) Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. Journal of Medicinal Chemistry. 56: 5675-90 |
Marsilje TH, Hedrick MP, Desharnais J, et al. (2003) 10-(2-benzoxazolcarbonyl)-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid: a potential inhibitor of GAR transformylase and AICAR transformylase. Bioorganic & Medicinal Chemistry. 11: 4503-9 |
Marsilje TH, Hedrick MP, Desharnais J, et al. (2003) Design, synthesis, and biological evaluation of simplified alpha-keto heterocycle, trifluoromethyl ketone, and formyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase. Bioorganic & Medicinal Chemistry. 11: 4487-501 |
Zhang Y, Desharnais J, Marsilje TH, et al. (2003) Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid. Biochemistry. 42: 6043-56 |
Greasley SE, Marsilje TH, Cai H, et al. (2001) Unexpected formation of an epoxide-derived multisubstrate adduct inhibitor on the active site of GAR transformylase Biochemistry. 40: 13538-13547 |
Boger DL, Marsilje TH, Castro RA, et al. (2000) Design, synthesis, and biological evaluation of fluoronitrophenyl substituted folate analogues as potential inhibitors of GAR transformylase and AICAR transformylase Bioorganic and Medicinal Chemistry Letters. 10: 1471-1475 |